GAITHERSBURG, Md., Sept. 8,
2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its novel
Matrix-M™ adjuvant, today announced that it will participate in two
upcoming investor conferences.
|
H.C. Wainwright 25th Annual Global
Investment Conference:
|
|
Fireside Chat
|
|
Date:
|
Monday, September 11,
2023
|
|
Time:
|
4:30 – 5:00 p.m.
Eastern Daylight Time (EDT)
|
|
Location:
|
Lotte New York Palace
Hotel
|
|
Moderator:
|
Vernon Bernardino,
Managing Director, Senior
Healthcare Analyst
|
|
Novavax
participants:
|
Jim Kelly, Executive
Vice President, Chief Financial
Officer and Treasurer and Robert Walker, Senior Vice
President, Chief Medical Officer
|
|
Conference
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Monday, September 11,
2023
|
|
|
Baird 2023 Global Healthcare
Conference:
|
|
Fireside Chat
|
|
Date:
|
Tuesday, September 12,
2023
|
|
Time:
|
10:15 – 10:45 a.m.
EDT
|
|
Location:
|
Intercontinental New
York Barclay Hotel
|
|
Moderator:
|
Joel L. Beatty, MD,
CFA, Senior Research Analyst –
Biotechnology
|
|
Novavax
participants:
|
Jim Kelly, Executive
Vice President, Chief Financial
Officer and Treasurer and Robert Walker, Senior Vice
President, Chief Medical Officer
|
|
Conference
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Tuesday, September 12,
2023
|
A replay of the recorded fireside sessions will be available
through the Events and Presentations page of the Company's website
at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID, influenza and COVID and influenza
combined. Please visit novavax.com and LinkedIn for more
information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-upcoming-september-conferences-301922087.html
SOURCE Novavax, Inc.